Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Myelofibrosis

NCT00522574 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT00522574
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00522574 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL019 Administered to Subjects With Myelofibrosis
Lead sponsor
Exelixis
Phase
Phase 1
Overall status
Terminated
Start date
August 31, 2007
Completion date
Not reported
Enrollment
100 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis, myeloproliferative disorders, polycythemia vera, thrombocythemia, essential